Our Team

Our Medtech focused team brings decades of experience from both sides of the Atlantic to venture and growth capital companies with the potential to dramatically improve the standard of care for patients, providers and payers

Find out more
Our Companies

We currently focus on growth stage Medtech companies and emerging Digital Health opportunities

Find out more
Our Entrepreneurs

We work with highly talented and creative entrepreneurs across the Medtech and Digital Health industries

Find out more
About the Firm

Endeavour Vision invests in medtech companies whose products will enhance and extend the lives of millions of people around the world.

Our current €250 million fund is one of the world’s largest dedicated Medtech funds with a team made up of highly experienced investors and experts. We are dedicated to supporting the growth of medtech companies across Europe and the United States.

Our mission is simple: work with people who share our vision of investing in and growing dynamic medtech businesses while delivering value for society as a whole.

Endeavour Vision is the clear partner of choice to help both entrepreneurs and investors succeed in transforming medical care.

"As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe."

Christopher M. Owens, President & CEO, Gynesonics

"As the founding investor in CeQur, Endeavour Vision has been a great partner over the years, providing strategic input, on-going support, and novel financing. The Endeavour Board Members bring a wealth of experience in R&D management, organizational management, marketing, regulatory affairs, clinical evaluation, and quality thus providing a resource for the CeQur management team to leverage as we work towards developing a successful product that will help thousands of patients with T2 diabetes achieve better glycemic control."

Robert Farra, CEO, CeQur Corporation

"We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organizational development and talent acquisition. They’re an investment team which works closely with management to identify creative solutions to complex issues, leading to maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner."

Earl R. Fender, President & CEO, Vertiflex

"Chrono Therapeutics has been very pleased and impressed with Endeavour Vision medical product experience and domain knowledge. They have been engaged, supportive, thoughtful partners, particularly in the areas of regulatory strategy and product development."

Alan Levy, former CEO, Chrono Therapeutics

"Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best."

Jacques R. Essinger, CEO, Symetis
Endeavour Vision News
Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*,  announced on 6 August that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a novel DARPin® therapy for the treatment of nAMD.

Find out more
Interview with Rob Barmann

"Diligence comes down to risk so whether it’s a VC or a strategic doing it, the goal is the same; to assess the level of risk for a transaction. What is different, is how that risk is defined and quantified. My goal in leading diligence was to focus our efforts on the handful of areas that we felt could completely disrupt our deal thesis. You will always miss something in diligence, but it is unacceptable to miss something that fundamentally changes the value of a deal."

Find out more
Interview with Kevin Hykes, President & CEO at Relievant

"There are 30 million patients in the United States that have chronic low back pain, it’s a massively debilitating condition that affects everything from personal relationships to careers. It is also one of the highest drivers of the national healthcare utilisation system. Our Intracept® Procedure is a minimally invasive outpatient treatment for pain associated with degenerative disc disease. The procedure targets the basivertebral nerve for the relief of chronic low back pain – it is extremely durable, has an excellent safety profile and is supported by an unparalleled portfolio of Level 1 clinical data."

Find out more
Portfolio Companies

Get in Touch

Endeavour Vision Ltd

6, rue de la Croix d’Or
1204, Geneva

+41 22 544 6000